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Timolol maleate is a non-selective beta-adrenergic receptor blocking agent with demonstrated efﬁcacy in
the treatment of open-angle glaucoma. A 76 year old female who presented with productive cough,
progressive dyspnea and hypoxia after starting timolol maleate opthalamic drops following glaucoma
surgery. The patient was diagnosed with interstitial lung disease secondary to timolol treatment and
after cessation of the offending agent along with corticosteroid treatment, symptoms improved drasti-
cally. Elimination of other possible causes of disease along with evolution of radiological and functional
signs left us with a diagnosis of timolol-induced interstitial lung disease. To our knowledge, this is the
second reported case of timolol-induced interstitial lung disease.
© 2015 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Several types of drugs can cause drug-induced interstitial lung
disease (DILD). Currently more than 300 medications are known to
cause DILD and this number will undoubtedly continue to increase
as the newer therapeutic agents hit the market. DILD is generally
described in terms of its clinical/histopathological features and thus
can be difﬁcult to diagnose as diagnosis is often possible by
exclusion alone [1]. Timolol maleate is a non-selective beta-
adrenergic receptor blocking agent used in treatment of open-angle
glaucoma and is a relatively well-tolerated drug. Little is known
about the adverse pulmonary effects associated with Timolol ma-
leate. It is important that health care providers be familiar with
possible adverse effects of medications they prescribe as prompt
recognition of the disease along with cessation of the offending
agent will minimize the risk morbidity and potential mortality. We
report a case of timolol-induced interstitial lung disease along with
a review of the literature.Case report
A 76 year old Caucasian female of French ethnicity with past
medical history of hypertension and glaucoma presented with a
three month history of productive cough and progressive dyspnea.Pulmonary Diseases, Florida
.A., 326 N Mills Ave, Orlando,
) 680 1191.
errero).
n open access article under the CPatient was seen by her primary care physician when symptoms
ﬁrst started and was diagnosed with bronchitis and treated with a
course of antibiotics. With no resolution of symptoms, patient was
treated with another course of antibiotics along with medrol dose
pack. Still with progressive symptoms patient underwent allergy
testing which was negative. Patient decided to seek treatment in
the emergency room. She denied a history of fevers, chills, weight
loss, chest pain, palpitations, chronic cough, hemoptysis, abdom-
inal pain, nausea, vomiting, diarrhea, asthma, rash, arthritis, rec-
reational drug abuse, exposure to pigeons or other birds, and
exposure to silicon, berillym, or asbestos. Patient denied family
history of pulmonary or cardiac problems. Other ambulatory
medicines included losartan and protonix. Upon examination,
blood pressure was 128/68 mm Hg, heart rate was 72 beats per
minute (bpm) and regular, a respiratory rate of 20 breaths per
minute, and temperature of 98.8. Pulmonary examination
revealed bibasilar rales with evidence of hypoxia with oxygen
saturation of 84% on room air. Cardiovascular, abdominal, and
neurological examinations were unremarkable. Complete blood
counts and chemistry panels were within normal limits. Blood
cultures were negative x 5 days. Sputum cultures were negative for
acid-fast bacilli, fungal, or pneumococcal growth. Chest CT revealed
a slight mosaic attenuation pattern of the lungs suggestive of air
trapping (Fig. 1A). A high resolution CT (HRCT) chest was recom-
mended. HRCT chest imaging revealed groundglass opacities and
mosaic pattern suggestive of bronchial air-trapping (Fig. 2). Bron-
choscopy with bronchoalveolar lavage was hypercellular with 89%
neutrophils, 8% lymphocytes, 2% monocytes, and 1% macrophages.
Transbronchial biopsy showed evidence of focal giant cell reactionC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A. Chest CT revealing mosaic pattern of the lungs with air trapping. B. Chest CT post-treatment reveals resolution of air trapping along with homogenous lung density.
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function test revealed FEV1 75% and decreased DLCO suggestive of
restrictive disease. The diagnosis of interstitial lung disease sec-
ondary to the use of timolol maleate was suspected and the
medication was stopped. The patient was started on methylpred-
nisolone treatment at a dose of 60 mg every 6 h with gradual
tapering to 5 mg oral daily over a 3 month period. Upon followup,
the patients symptoms had resolved. Repeat CT of the chest
revealed no evidence of parenchymal inﬁltrates with complete
resolution of any signs of air trapping (Fig. 1B). The patients with
oxygen saturation was noted to be 96% on room air.Discussion
Adverse drug reactions are the seventh most common cause of
death [2]. Drug induced pulmonary disease is an underdiagnosed
issue. The global incidence of interstitial lung disease is not clearly
known, but 2.5e3% of cases are drug induced [3,4]. Disparities in
incidence regarding drug-induced interstitial lung disease in
different ethnic groups have been reported. Recent studies have
shown timolol maleate is metabolized by CYP2D6, a member of the
cytochrome P450 family. In patients who are CYP2D6 poor
metabolizers, systemic timolol concentrations may be high enoughFig. 2. HRCT chest revealing presence of areas of heterogeneous with increase in lung
density and multiple areas of air trapping.to cause respiratory and cardiovascular adverse effects (5e10%
Caucasians, 1e2% Asians) [5]. Timolol maleate is a non-selective
beta-adrenergic receptor blocking agent used in treatment of
open-angle glaucoma. Unlike the oral route which undergoes
extensive ﬁrst pass hepatic metabolism, the topical route drains
into the lacrimal ducts where systemic absorption occurs via facial
and opthalamic veins which results in higher concentrations
reaching systemic circulation [6]. Drugs in the same therapeutic
class can induce similar pulmonary toxicity patterns [7]. Opthala-
mic administration of beta-adrenergic receptor blockers cause
similar effects to those reported with oral beta-adrenergic receptor
blockers with the most frequent being bronchospasm. Also re-
ported are bradycardia, pleural and perdicardial effusion, bron-
chiolitis obiterans organizing pneumonia, and interstitial lung
disease.
Although based on recent guidelines, clinical history and HRCT
imaging of the chest is deemed sufﬁcient enough for diagnosis of
interstitial lung disease [8] bronchoalveolar lavage is generally
indicated to exclude an infection and to support a drug etiology [9]
A lymphocytic predominance is most frequently seen in analysis
although neutrophilic, mixed lymphocytic and neutrophilic and or
eosinophilic pattern has been reported less frequently [10] There
has not been a risk-beneﬁt analysis regarding lung biopsy vs con-
servative management in regards to drug-induced lung disease
however in regards to drug induced interstitial pneumonitis, lung
biopsy is rarely needed to conﬁrm the diagnosis as it is not
pathognomonic for drug toxicity and most cases tend to respond to
withdrawal of the offending agent with or without corticosteroid
therapy [11]. Transbronchial lung biopsy has been shown to have a
diagnostic rate of 76% in drug induced lung disease cases [12]
Pulmonary function testing demonstrates restrictive lung disease
pattern with decreased total lung capacity, residual volume, forced
vital capacity, and diffusion capacity, with the latter suggestive of
an alveolarecapillary interface disturbance [13]. Although drug
provocation testing may be the most convincing test to conﬁrm
drug induced interstitial lung disease, rechallenged patients run
the risk of severe or fatal interstitial lung disease following re-
exposure and is generally considered unethical [1].
The pathophysiology of timolol induced interstitial lung disease
is still unknown. The physiological mechanisms underlying iatro-
genic lung disease include direct cellular toxicity, cellular edema,
alveo-capillary membrane leakage, activation of the inﬂammatory
cascade and immunological phenomenon [14].
Treatment needs to be individualized based on response to
therapy and presence or absence of side-effects, with the endpoint
being to prevent deposition of ﬁbrotic tissue via suppression of the
inﬂammatory response. There is a paucity of data regarding
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disease, thus ﬁrm recommendations cannot be made. Steroids are
indicated in patients with extensive opacities on imaging, patients
with signiﬁcant hypoxemia, or in patients in whom drug with-
drawal fails to translate into a deﬁnite improvement [9] Based on
published case studies, recommendations of high dose methyl-
prednisoline (1 g daily for 3 days) for patients with respiratory
failure and lower doses of methylprednisolone (1 mg/kg every 6 h)
for less severe cases have been reported with successful results
[15,16].
The diagnosis of drug induced interstitial lung disease depends
on a temporal association between exposure to causative agent and
development of respiratory signs and symptoms [1]. We believe
timolol maleate is responsible for the development of interstitial
lung disease in our patient due to the following reasons:
First and foremost, other causes of lung damage were excluded
including infectious, collagen vascular diseases, occupational ex-
posures, other medication exposures, and malignancy. Lipoid
pneumonia has been associated with angiotensin converting
enzyme inhibitor drugs but has not been demonstrated with use of
angiotensin receptor blocking agents [17]. Furthermore, there is no
lipid excipients in timolol eyedrops, there was no lipid density in
scanner, and no fat inclusions seen in bronchoalveolar lavage
marcrophages. The Naranjo adverse drug reaction probability scale
with a ﬁnal score of six, indicated a probable relation between
timolol and development of lung disease [18]. The removal of
opthalamic treatment brought about resolution of symptoms and
radiographic ﬁndings (with the addition of corticosteroid
treatment).
Conclusions
To our knowledge, this is the second literature report of inter-
stitial lung disease related to timolol maleate treatment. This report
is similar to the prior literature report in regards to presentation
and workup leading to the diagnosis of timolol maleate induce lung
disease but differs in treatment. We decided to use steroids as a
treatment option in addition to stopping the offending agent. This
decision was based on more recent anecodotal case reports which
have shown a beneﬁcial effect of steroids in ameliorating symp-
toms and resolution of interstitial lung disease. In the clinical
setting, the persistence of dyspnea after timolol usage should urge
the physician to order a CT scan of the chest. Interstitial lung disease
should be considered in the differential diagnosis and the sus-
pected offending agent should be withheld. Drug inducedinterstitial lung disease carries a good prognosis and the develop-
ment of lung ﬁbrosis following early recognition and treatment of
this condition is rare.Funding
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